Abstract
Plasmid pTETnir 15 which directs the expression of the non–toxic immunogenic fragment C of tetanus toxin from the anaerobically inducible nirB promoter, was introduced into the Salmonella typhimurium aroA aroD live oral vaccine strain BRD509. The resulting strain, designated BRD847, was used to vaccinate orally BALB/c mice and was tested for plasmid stability and its ability to protect against a lethal tetanus toxin challenge. PTET nir15 was stably inherited by bacteria growing or persisting in the tissues of immunized mice whereas another BRD509 derivative, designated BRD753, harboring plasmid pTET85 which directs fragment C expression from the tac promoter, was highly unstable. Mice immunized with a single oral dose of BRD847 developed high levels of circulating anti–fragment C antibodies and were solidly protected against tetanus toxin challenge. Mice immunized with a single oral dose of BRD753 developed no detectable anti–fragment C antibodies. After boosting, antibodies were detected, but the mice were only partially protected against tetanus toxin challenge. Thus the use of an in vivo inducible promoter such as nirB may be a generally applicable approach to obtaining the stable in vivo expression of heterologous antigens in Salmonella vaccine strains.
Similar content being viewed by others
Article PDF
References
Germanier, R. and Furer, E. 1975. Isolation and characterisation galE mutant Ty2la of Satrnvnella typhi: a candidate strain for a live oral tvphoid vaccine. J. Infect. Dis. 131: 553–558.
Levine, M.M., Fericcio, C., Black, R.K., Germanicr, R. and Chilean Typhoid Committee 1987. Large scale field trial of Ty21a live oral typhoid vaccine in enteric coated capsule formulation. Lancet (i): 1049–1052.
Hoiseth, S.K. and Stocker, B.A.D. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291: 238–240.
O'Callaghan, D., Maskell, D., Liew, F.Y., Easmon, C.S.F. and Dougan, G. 1988. Characterisation of aromatic- and purine-dependent Salmonella typhimurium: attenuation, persistence, and ability to induce protective immunity in BALB/c mice. Infect. Immun. 56: 419–426.
Mukkur, T.K.S., McDowell, G.N., Stocker, B.A.D. and Lascelles, A.K. 1987. Protection against saimonellosis in mice and sheep by immunisation with aromatic-dependent Salmonella typhimurium . J. Med. Microbiol. 24: 11–19.
Jones, P.W., Dougan, G., Hayward, C., Mackensie, N., Collins, P. and Chatfield, S.N. 1991. Oral vaccination of calves against experimental salmonellosis using a double aro mutant of Salmonella typhimurium . Vaccine 9: 29–36.
Casper, G.L., Nicholas, R.A.J., Cullen, G.A. and Hormache, C.E. 1990. Vaccination of chickens with a Salmonella ententidis aroA live oral Salmonella vaccine. Microbiol. Pathogen. 9: 255–265.
Dougan, G., Hofnung, M., Lanzavecchia, A. and Leclerc, C. Immune response to proteins with recombinant epitopes, perspectives for vaccines, p. 171–220. In: Conferences Philipe Laudat 1990 INSERM, Paris.
Newton, S.M.C., Jacob, C.O. and Stocker, B.A.D. 1989. Immune response to cholera toxin epitope inserted in Salmonella flagellin. Science 244: 70–72.
Tite, J.P., Gao, X.M., Hughes Jenkins, M., Lipscombe, M., O'Callaghan, D., Dougan, G. and Liew, F.Y. 1990. Anti-viral immunity induced by recombinant nucleoprotein of Influenza A virus. III. Delivery of recombinant nucleoprotein to the immune system using attenuated Salmonella typhimurium as a liver carrier. Immunology 70: 540–547.
Sadoff, J.C., Ballou, W.R., Baron, L.S., Majarian, W.R., Brey, R.N., Hockmeyer, W.T., Young, J.F., Cryz, J.J., Ou, J., Lowell, G.H. and Chulay, J.D. 1988. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240: 236–238.
Fairweather, N.F., Chatfield, S.N., Makoff, A.J., Strugnell, R.A., Bester, J., Maskell, D.J. and Dougan, G. 1990. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect. Immun. 58: 1323–1329.
Chatfield, S.N., Fairweather, N.F., Charles, I., Pickard, D., Levine, M., Hone, D., Posada, M., Strugnell, R.A. and Dougan, G. 1992. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Infect. Immun: 10: 53–60.
Stanfield, J.P. and Galazka, A. 1984. Neonatal tetanus in the third world today. Bull. WHO 62: 647–669.
Amann, E., Brosius, J. and Ptashne, M. 1983. Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli . Gene 25: 167–178.
Peakman, T., Crouzet, J., Jayaux, J.F., Busby, S., Mohan, S., Harborne, N., Wooton, J., Nicholson, R. and Cole, J. 1990. Nucleotide sequence, organisation and structural analysis of the products of genes in the nirB-cysB region of the Escherichia coli K-12 chromosome. Eur. J. Biochem. 191: 315–323.
Oxer, M.D., Bently, C.M., Doyle, J.G., Peakman, T.C., Charles, I.G. and Makoff, A.J. 1991. High level heterologous expression in E. coli. using the anaerobically-activated nirB promoter. Nucl. Acids Res. 19: 1889–1892.
Bullas, L.R. and Ryu, J.I. 1983. Salmonella typhimurium LT2 strains which are r-m+ for all three chromosomally located systems of DNA restriction and modification. J. Bacteriol. 156: 471–474.
Hone, D., Attridge, S. Van den Bosch, L. and Hackett, J. 1988. A chromosomal integration system tor stabilisation of heterologous genes in Salmonella based vaccine strains. Microbial Pathogen. 5: 407–418.
Nakayama, K., Kelly, S.M. and Curtiss, R. 1988. Construction of an Asd expression-cloning vector: stable maintenance and high levels expression of cloned genes in a Salmonella vaccine strain. Bio/Technology 6: 693–697.
Strugnell, R.A., Maskell, D., Fairweather, N., Pickard, D., Cockayne, A., Penn, C. and Dougan, G. 1990. Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene 88: 57–63.
Jayaraman, P.S., Peakman, T.C., Busby, S.J.W., Quincey, R.V. and Cole, J.A. 1987. Location and sequence of the promoter of the gene for the NADH-dependent nitrite reductase of Escherichia coli and its regulation by oxygen, the Fnr protein and nitrite. J. Mol. Biol. 196: 781–788.
Bell, A.I., Gaston, K.L., Cole, J.A. and Busby, S.J.W. 1989. Cloning of binding sequences for the Escherichia coli transcription activators, FNR and CRP: location of bases involved in discrimination between FNR and CRP. Nucl. Acids Res. 17: 3865–3874.
Jayaraman, P.S., Cole, J.A. and Busby, S.J.W. 1989. Mutational analysis of the nucleotide sequence at the FNR-depeiident nirB promoter in Escherichia coli . Nucl. Acids Res. 17: 135–145.
Stover, C.K., de la Cruz, V.F., Fuerst, T.R., Burlein, J.E., Benson, L.A., Bennet, L.T., Bansal, G.P., Young, J.F., Lee, M.H., Hatful, G.F., Snapper, S.B., Barletta, R.G., Jacobs, W.R. and Bloom, B.R. 1991. New use of BCG for recombinant vaccines. Nature 351: 456–460.
Davis, R.W., Bostein, D. and Roth, J.R. 1980. Advanced Bacterial Genet ics. A Manual for Genetic Engineering. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
Makoff, A.J., Oxer, M.D., Romanos, M.A., Fairweather, N.F. and Ballantine, S. 1989. Expression of tetanus toxin fragment C. in E. coli: high level expression by removing rare codons. Nucl. Acids Res. 17: 10191–10202.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chatfield, S., Charles, I., Makoff, A. et al. Use of the nirB Promoter to Direct the Stable Expression of Heterologous Antigens in Salmonella Oral Vaccine Strains: Development of a Single–Dose Oral Tetanus Vaccine. Nat Biotechnol 10, 888–892 (1992). https://doi.org/10.1038/nbt0892-888
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nbt0892-888
This article is cited by
-
The anti-vaccination movement and resistance to allergen-immunotherapy: a guide for clinical allergists
Allergy, Asthma & Clinical Immunology (2010)
-
Salmonella enterica serovar Typhi live vector vaccines finally come of age
Immunology & Cell Biology (2009)
-
Expression of foreign proteins in a Vibrio cholerae vaccine strain using the stationary phase hemagglutinin/protease promoter
Biotechnology Letters (2007)
-
Papillomavirus Vaccines
Clinical Immunotherapeutics (1994)